BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...Inc. (NASDAQ:BTAI) hired Javier Rodriguez as chief legal officer. He was chief legal officer at Indivior plc...
BioCentury | Feb 11, 2020
Politics, Policy & Law

Senate bill introduced to close Orphan drug ‘loophole’

...and distribution costs. Controversy over Orphan exclusivity for opioid use disorder therapy Sublocade buprenorphine from Indivior plc...
...revoked the drug’s Orphan status after finding that its initial decision was “erroneous.” Steve Usdin, Washington Editor Indivior plc U.S...
BioCentury | Jan 29, 2020
Politics & Policy

House bill seeks to tweak Orphan Drug Act, could pose threat to pathway

...a recent controversy over Orphan exclusivity for an opioid use disorder therapy Sublocade buprenorphine from Indivior plc...
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...Scott Olsen following his retirement, effective January. She is VP of global government affairs at Indivior plc...
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

...Ponni Subbiah as SVP, global head of medical affairs and CMO. She was CMO at Indivior plc...
BioCentury | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

...SEC filing Columbia will receive a six-digit license fee and is eligible for single-digit royalties. Indivior plc...
BioCentury | Apr 10, 2019
Company News

U.S. fraud charges pummel Indivior shares

...sublingual film. Wednesday's move translates to a market cap loss of £551.9 million ($721.9 million). Indivior plc...
...11 patents related to Suboxone buprenorphine/naloxone sublingual film. The DOJ alleges in the indictment that Indivior...
...companies have launched generic versions in the U.S., in addition to Indivior's own authorized generic. Indivior...
BioCentury | Feb 22, 2019
Company News

Generic Suboxone products enter U.S. market

...launched in the U.S. generic versions of opioid dependence drug Suboxone buprenorphine/naloxone sublingual film from Indivior plc...
...denying Indivior's motion to restrict Dr. Reddy's from launching its generic to the U.S. market. Indivior...
...Market Opioid Dependence Generic" ). Indivior reported $1.1 billion in 2018 U.S. sales of Suboxone. Indivior plc...
BioCentury | Feb 15, 2019
Company News

Indivior divests Suboxone tablets to China’s Zhejiang Pukang

...so that Indivior can focus on long-term growth of its extended release injectable drug formulations. Indivior...
...4Q19. Indivior plc (LSE:INDV), Richmond, Va. Zhejiang Pukang Biotechnology Co. Ltd., Hangzhou, China Business: Neurology Hongjiang Li Suboxone, buprenorphine/naloxone Indivior plc Zhejiang...
BioCentury | Jan 4, 2019
Clinical News

‘Tentative’ FDA approval for Braeburn's opioid addiction product

...through November 2020 that was granted to opioid use disorder drug Sublocade subcutaneous buprenorphine from Indivior plc...
...to SEK66.90 on Dec. 28. Its shares did not trade Dec. 24 through Dec. 26. Indivior...
...Brixadi buprenorphine (CAM2038) Business: Neurology Sandi Wong CAM2038, buprenorphine Sublocade (Brand), RBP-6000 (Compound #), buprenorphine (Generic) Braeburn Pharmaceuticals Inc. Camurus AB Indivior plc Addiction Brixadi Buvidal opioid...
Items per page:
1 - 10 of 59
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...Inc. (NASDAQ:BTAI) hired Javier Rodriguez as chief legal officer. He was chief legal officer at Indivior plc...
BioCentury | Feb 11, 2020
Politics, Policy & Law

Senate bill introduced to close Orphan drug ‘loophole’

...and distribution costs. Controversy over Orphan exclusivity for opioid use disorder therapy Sublocade buprenorphine from Indivior plc...
...revoked the drug’s Orphan status after finding that its initial decision was “erroneous.” Steve Usdin, Washington Editor Indivior plc U.S...
BioCentury | Jan 29, 2020
Politics & Policy

House bill seeks to tweak Orphan Drug Act, could pose threat to pathway

...a recent controversy over Orphan exclusivity for an opioid use disorder therapy Sublocade buprenorphine from Indivior plc...
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...Scott Olsen following his retirement, effective January. She is VP of global government affairs at Indivior plc...
BioCentury | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

...Ponni Subbiah as SVP, global head of medical affairs and CMO. She was CMO at Indivior plc...
BioCentury | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

...SEC filing Columbia will receive a six-digit license fee and is eligible for single-digit royalties. Indivior plc...
BioCentury | Apr 10, 2019
Company News

U.S. fraud charges pummel Indivior shares

...sublingual film. Wednesday's move translates to a market cap loss of £551.9 million ($721.9 million). Indivior plc...
...11 patents related to Suboxone buprenorphine/naloxone sublingual film. The DOJ alleges in the indictment that Indivior...
...companies have launched generic versions in the U.S., in addition to Indivior's own authorized generic. Indivior...
BioCentury | Feb 22, 2019
Company News

Generic Suboxone products enter U.S. market

...launched in the U.S. generic versions of opioid dependence drug Suboxone buprenorphine/naloxone sublingual film from Indivior plc...
...denying Indivior's motion to restrict Dr. Reddy's from launching its generic to the U.S. market. Indivior...
...Market Opioid Dependence Generic" ). Indivior reported $1.1 billion in 2018 U.S. sales of Suboxone. Indivior plc...
BioCentury | Feb 15, 2019
Company News

Indivior divests Suboxone tablets to China’s Zhejiang Pukang

...so that Indivior can focus on long-term growth of its extended release injectable drug formulations. Indivior...
...4Q19. Indivior plc (LSE:INDV), Richmond, Va. Zhejiang Pukang Biotechnology Co. Ltd., Hangzhou, China Business: Neurology Hongjiang Li Suboxone, buprenorphine/naloxone Indivior plc Zhejiang...
BioCentury | Jan 4, 2019
Clinical News

‘Tentative’ FDA approval for Braeburn's opioid addiction product

...through November 2020 that was granted to opioid use disorder drug Sublocade subcutaneous buprenorphine from Indivior plc...
...to SEK66.90 on Dec. 28. Its shares did not trade Dec. 24 through Dec. 26. Indivior...
...Brixadi buprenorphine (CAM2038) Business: Neurology Sandi Wong CAM2038, buprenorphine Sublocade (Brand), RBP-6000 (Compound #), buprenorphine (Generic) Braeburn Pharmaceuticals Inc. Camurus AB Indivior plc Addiction Brixadi Buvidal opioid...
Items per page:
1 - 10 of 59